Error: Twitter did not respond. Please wait a few minutes and refresh this page.
Monthly Archives: June 2011
Varenaciline is marketed by Pfizer world wide as Chandix or Champix. Varenaciline is marketed as tartarate salt form, this salt form is protected by US patent 6890927 and its indian equivalent is 204091 (863/MUMNP/2003). This ‘091 patent is opposed by Dr … Continue reading
A new pre grant opposition decision is published by patent office which is related to palonosetron. Application No: 1024/MUMNP/2005, Assignee: Helsinn Healthcare, Title: “Use of palonosetron treating postoperative nausea and vomiting“. This application is opposed by glenmark and Sun pharma. This … Continue reading
A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1). This application is refused under lack of inventive … Continue reading
We aware that Erlotinib product patent is granted in India as 196774 (537/DEL/1996) and is is subject of many patent infringement cases filed at Delhi high court. Applicant has a divisional application (2018/CHE/2006) of ‘774 patent, which is pending at IPO Chennai. … Continue reading
[WSJ] [Bloomberg] [Pharmaletter] EPO last Friday revokes EP1020461, which covers magnesium salt of Esomeprazole and it is divisional patent of EP0652872 (product patent). ‘461 patent revocation status not yet updated in European patent register. ‘461 patent was opposed by many companies including Teva, Hexal, Lupin etc. … Continue reading